Dabur Research Foundation

Dabur Pharma Limited

Other

Fresenius Kabi Oncology Limited

Council of Scientific and Industrial Research

Rama Mukherjee

Anand C Burman

Manu Jaggi

Sudhanand Prasad

Anu T Singh

Dhiraj Khattar

Mukesh Kumar

Archna Mathur

Manoj Kumar Singh

Rajan Sharma

Kamal K Kapoor

Sarjana Dutt

Shobhit Kumar Singh

Gautam R Desiraju

Praveen Rajendran

Deepak Prusthy

Pawan Kumar Gupta

Rajendran Praveen

Neena Gupta

Honey Bala

Sanjoy Mullick

Mukund Keshav Gurjar

Jhillu Singh Yadav

Sanjeeb Kumar Sahoo

Arabinda Chaudhuri

Prasanta Kumar Ghosh

Srivari Chandrasekhar

Vivek Kumar

Anand Vardhan

Amarnath Maitra

Mohammad Jamshed Ahmed Siddiqui

Manju Ray

Radhika Dilip Wakharkar

Shiv Kumar Agarwal

Rajesh Srivastava

Ashwini Nangia

Hanumant Bapu Rao Borate

Anuo T Singh

Sanjay Sarkhel

K V V M Sairam

Yenugonda Venkata Mahidhar

Tushar Kanti Chakraborty

Ajit Chand Kunwar

Sanjay Kumar Srivastava

Asish Kumar Banerjee

Venkatachalam Sesha Giri

Sankar Kumar Dutta

Kalapatapu V V M Sairam

Hemant Kumar Jajoo

Rinku Ahuja

Anil K Mishra

Nidhi Rani

Lazar T Mathew

Archana Mathur

Rajiv Kumar Shrivastava

Soumendu Paul

Dinesh Kumar

Praveen Khullar

Perundurai S Srinivasan

Kapil Maithal

Paromita Sengupta

Dhatchana Moorthy Nachiappan

The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidne (VP), N-Isopropylactylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.

Biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions

The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidone (VP), N-Isopropylacrylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.

The present invention provides processes for the synthesis of novel Shikimic acid head-group containing non-toxic cationic amphiphiles capable of facilitating transport of biological macromolecules into cells.

Process for synthesis of glycomimicking cationic amphiphiles

The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C(&#x2550;CH)CHor CH(CH); Rtogether with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; Ror Rare hydrogen or aryl with the proviso that both are not independently hydrogen or alkyl or Rand Rare combined together to form an aryl ring optionally substituted with a group X, wherein X is selected from halogen, alkyl, cyano, nitro, alkoxy, amino or substituted amine; Y is N or O; and Ris zero when Y is O, and Ris hydrogen, alkyl or aryl alkyl when Y is N, useful for inhibition of tumor cancer cells. 

Betulinic acid derivatives

The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of anticancer activity. The invention also relates to pharmaceutical compositions containing a combination of such peptide analogs.

Drug comprising synthetic peptide analogs for the treatment of cancer

A stabilized pharmaceutical composition of anticancer drug and a solvent like Polyethoxylated castor oil (cremophor) also containing any other suitable solubilizer suitable for human administration like dehydrated alcohol, is disclosed. Compositions prepared using this purified polyethoxylated castor oil enhance the stability of paclitaxel in such compositions.

Stabilized formulation

The invention relates to the use of derivatives of cyclopentenone for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of derivatives of cyclopentenone for the inhibition and/or prevention of cancer of the colon, pancreas, larynx, ovary, duodenum, kidney, oral cavity, prostate, lung, endothelial cells and leukemias.

Cyclopentenone derivatives for cancer therapy

The present invention encompasses novel analogs of vasoactive intestinal peptide (VIP), containing substitutions at appropriately selected amino acids. The invention particularly relates to the design and synthesis of novel biologically active VIP analogs containing &#x3b1;, &#x3b1;-dialkylated amino acids in a site-specific manner. Specifically, the invention relates to the synthesis of VIP peptide derivatives, which bind selectively to VIP receptors on target cells. The invention encompasses methods for the generation of these peptides, compositions containing the peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.

Vasoactive intestinal peptide analogs

Anticancer peptides which incorporate furanoid sugar amino acids and compositions made using these peptides are described. Methods for synthesis of the peptides and for preparing the furanoid sugar amino acids are disclosed. The peptides and compositions made using the peptides have pharmacological applications of these peptides especially in the treatment and prevention of cancer and tumors.

Peptides comprising furanoid sugar amino acids for the treatment of cancer

The present invention encompasses novel peptides that are antagonists to bombesin and bombesin like peptides and are useful in the treatment of cancer. The invention particularly relates to the design and synthesis of the novel peptides incorporating &#x3b1;,&#x3b1;-amino acids in a site specific manner. The invention encompasses methods for the generation of these peptides, compositions containing the peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.

Bombesin analogs for treatment of cancer

The invention relates to the use of novel anthracene based compounds for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of hydroanthracene based compounds for the inhibition and/or prevention of cancer of the colon, pancreas, prostate, lung, larynx, ovary, breast, glioblastoma, oral cavity, endothelial cells and leukemias. The agents of the invention form a distinct class, distinct from the anthracene, anthrone or anthraquinone derivatives.

Hydroanthracene based compounds as anticancer agents

A polypeptide of the formula (I),P-L-P-L-P-L-P.

Polypeptides of covalently linked synthetic bioactive peptide analog(s) for treatment of cancer

This invention relates to novel antiproliferative and anti secrectory peptides that are inhibitory to vasoactive intestinal peptide receptor and are useful in the treatment of cancer. The invention particularly relates to the synthesis of lipid-peptide conjugates containing fatty acids of different sizes, which inhibits the binding of VIP to its receptors. The invention encompasses methods for generation of these peptides, composition containing these peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.

Peptides for treatment of cancer

The present invention provides compositions and methods for the solubilization of poorly soluble drugs such as triterpenes like betulinic acid and/its derivatives in pharmaceutically acceptable liquid vehicles that avoid use of potentially toxic solvents that are often used for the solubilization of poorly soluble drugs. In the compositions of this invention the drugs remain physically and chemically stable and can be administered intravascularly without undue toxicity from undissolved drug and/or from the solvent vehicles at a drug dose meant to be effective to exhibit clinically significant anticancer activity.

Method and compositions for solubilization of pentacyclic triterpenes

Growing community of inventors

Ghaziabad, India

Rama Mukherjee